2013
DOI: 10.1007/s11095-013-0971-1
|View full text |Cite
|
Sign up to set email alerts
|

Delivery Systems and Local Administration Routes for Therapeutic siRNA

Abstract: With the increasing number of studies proposing new and optimal delivery strategies for the efficacious silencing of gene-related diseases by the local administration of siRNAs, the present review aims to provide a broad overview of the most important and latest developments of non-viral siRNA delivery systems for local administration. Moreover, the main disease targets for the local delivery of siRNA to specific tissues or organs, including the skin, the lung, the eye, the nervous system, the digestive system… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
61
0
12

Year Published

2014
2014
2023
2023

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 92 publications
(73 citation statements)
references
References 136 publications
0
61
0
12
Order By: Relevance
“…22 Thus, nonviral siRNA delivery systems based on polymers, lipids, and proteins have been developed. [23][24][25] Low-density lipoprotein (LDL) isolated from human plasma contains a hydrophobic core surrounded by a phospholipid monolayer with apolipoprotein B-100, which can be recognized by the LDL receptor (LDLr) that is abundantly expressed in tumor membranes via active lysine residues.…”
Section: Introductionmentioning
confidence: 99%
“…22 Thus, nonviral siRNA delivery systems based on polymers, lipids, and proteins have been developed. [23][24][25] Low-density lipoprotein (LDL) isolated from human plasma contains a hydrophobic core surrounded by a phospholipid monolayer with apolipoprotein B-100, which can be recognized by the LDL receptor (LDLr) that is abundantly expressed in tumor membranes via active lysine residues.…”
Section: Introductionmentioning
confidence: 99%
“…21 Recently, local gene delivery systems have yielded promising results, some of which are currently undergoing testing in clinical trials. 22 Vascular endothelial growth factor (VEGF) is an important angiogenic factor. One of its key functions is stimulating vasculogenesis and angiogenesis.…”
Section: Introductionmentioning
confidence: 99%
“…Na fase de execução, o siRNA e o miRNA são incorporados em complexos proteicos denominados RISC (RNA Induced Silencing Complex). Uma helicase presente neste complexo abre a dupla-fita do siRNA, a fita antisense é usada como guia para reconhecer o RNAm alvo, que é clivado pelo complexo, degradando-o (DE PAULA; BENTLEY; MAHATO, 2007;ELBASHIR;LENDECKEL;TUSCHL, 2001;VICENTINI et al, 2013b;WHITEHEAD;ANDERSON, 2009 MAHATO, 2007;MASIERO et al, 2007;WHITEHEAD;ANDERSON, 2009), isto porque em princípio qualquer alvo pode ser inibido, o siRNA é especifico, facilmente sintetizado e será sempre uma molécula com as mesmas características físico-químicas (BUMCROT et al, 2006;DAKA;PEER, 2012;XU;WANG, 2015). RNAi tem mostrado potencial para tratar diversas doenças incluindo desordens da pele (JACOBSON et al, 2010;VICENTINI et al, 2013a), aterosclerose (LI et al, 2010), câncer (ABBASI et al, 2011;ARIMA et al, 2012;HSU et al, 2013;TARATULA et al, 2011) e infecções virais (ALVAREZ et al, 2009;BITKO et al, 2005;DEVINCENZO et al, 2008DEVINCENZO et al, , 2010LI et al, 2005;ZAMORA et al, 2011).…”
Section: Interferência Por Rna (Rnai)unclassified